— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected.
— Revenue jumped threefold to $44.8 million, versus $29.3 million expected. The results were helped by higher license fees and lower operating expenses.
— For fiscal 2020, company expects revenues between $60 million and $65 million. Operating expenses are projected to be between $165 million and $170 million.
— IMGN shares shot up 5.4% immediately following the announcement.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Baidu (BIDU) Q2 earnings rise unexpectedly; stock falls
https://www.youtube.com/watch?v=50yUaLybUnA&t=667s China-based internet search firm Baidu Inc. (NASDAQ: BIDU) reported financial results for the second quarter of 2020 on Thursday after the market's close. Earnings exceeded analysts’ expectations, but the
Applied Materials (AMAT) tops Q3 2020 targets; provides Q4 outlook
Applied Materials' (NASDAQ: AMAT) earnings and revenue for the third quarter exceeded the market's views. Adjusted EPS of $1.06 and revenue of $4.40 billion in Q3, grew 43% and 23%,
Is Altimmune (ALT) stock a buy right now?
A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or in the treatment of COVID-19. While these companies